DK3255146T3 - Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter - Google Patents

Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter Download PDF

Info

Publication number
DK3255146T3
DK3255146T3 DK17169885.5T DK17169885T DK3255146T3 DK 3255146 T3 DK3255146 T3 DK 3255146T3 DK 17169885 T DK17169885 T DK 17169885T DK 3255146 T3 DK3255146 T3 DK 3255146T3
Authority
DK
Denmark
Prior art keywords
histidyl
compositions
methods
biological activities
trna synthetase
Prior art date
Application number
DK17169885.5T
Other languages
English (en)
Inventor
Jie Zhou
Ching Fun Lau
Zhiwen Xu
Wing Sze Lo
Kristi Helen Piehl
Leslie Ann Greene
Original Assignee
Pangu Biopharma Ltd
Atyr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangu Biopharma Ltd, Atyr Pharma Inc filed Critical Pangu Biopharma Ltd
Application granted granted Critical
Publication of DK3255146T3 publication Critical patent/DK3255146T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
    • C12Y601/01021—Histidine-tRNA ligase (6.1.1.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
DK17169885.5T 2009-03-16 2010-03-16 Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter DK3255146T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16063009P 2009-03-16 2009-03-16
US23974709P 2009-09-03 2009-09-03
EP10753998.3A EP2408905B1 (en) 2009-03-16 2010-03-16 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities

Publications (1)

Publication Number Publication Date
DK3255146T3 true DK3255146T3 (da) 2019-08-19

Family

ID=42740199

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17169885.5T DK3255146T3 (da) 2009-03-16 2010-03-16 Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter
DK10753998.3T DK2408905T3 (da) 2009-03-16 2010-03-16 Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10753998.3T DK2408905T3 (da) 2009-03-16 2010-03-16 Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter

Country Status (10)

Country Link
US (8) US8404242B2 (da)
EP (2) EP2408905B1 (da)
JP (4) JP5730280B2 (da)
CN (3) CN107574157A (da)
AU (1) AU2010226726B8 (da)
CA (1) CA2755784C (da)
DK (2) DK3255146T3 (da)
ES (2) ES2638779T3 (da)
HK (1) HK1247243B (da)
WO (1) WO2010107825A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307046B1 (en) * 2008-06-11 2017-01-25 aTyr Pharma, Inc. Thrombopoietic activity of tyrosyl-trna synthetase polypeptides
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
CA2755784C (en) 2009-03-16 2020-03-24 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
EP2414513B1 (en) 2009-03-31 2015-10-28 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
AU2010278711A1 (en) 2009-07-31 2012-02-23 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
ES2535951T3 (es) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidil ARNt sintetasas para reducir la inflamación
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
US20110150885A1 (en) * 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
US8828685B2 (en) * 2010-02-04 2014-09-09 The Scripps Research Institute Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
AU2011248521B2 (en) 2010-04-27 2017-03-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011139988A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
EP2566492B1 (en) 2010-05-04 2016-10-26 aTyr Pharma, Inc. Innovative discovery of therapeutic compositions related to protein fragments of glutamyl-prolyl-trna synthetases
JP6396656B2 (ja) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ， インコーポレイテッド ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US20130202576A1 (en) * 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
EP2624857B1 (en) 2010-10-06 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl trna synthetases
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CN104220461A (zh) 2011-12-29 2014-12-17 Atyr医药公司 天冬氨酰-tRNA合成酶-FC缀合物
RU2659423C2 (ru) 2012-02-16 2018-07-02 ЭйТИР ФАРМА, ИНК. ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
DK3460054T3 (da) * 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
EP4023294A1 (en) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating alzheimer's disease
KR101899591B1 (ko) * 2015-02-26 2018-09-17 재단법인 의약바이오컨버젼스연구단 트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물
WO2016159009A1 (ja) * 2015-03-31 2016-10-06 国立大学法人岡山大学 癌検出キット、および、癌診断のためのデータの取得方法
KR101771068B1 (ko) * 2015-07-14 2017-08-24 재단법인 의약바이오컨버젼스연구단 케모카인 활성을 가지는 신규한 폴리펩타이드
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020517638A (ja) * 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
CA3061787A1 (en) 2017-05-15 2018-11-22 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
US20200085925A1 (en) * 2018-07-26 2020-03-19 Atyr Pharma Inc. Compositions and methods for treating nrp2-associated diseases
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5766960A (en) 1987-07-27 1998-06-16 Australian Membrane And Biotechnology Research Institute Receptor membranes
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US6309822B1 (en) 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5556645A (en) 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5936731A (en) 1991-02-22 1999-08-10 Applied Spectral Imaging Ltd. Method for simultaneous detection of multiple fluorophores for in situ hybridization and chromosome painting
US5981606A (en) 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5484703A (en) 1993-04-22 1996-01-16 United States Of America Assay using recombinant histidyl-tRNA synthetase
DE69431719T2 (de) 1993-06-25 2003-09-18 Affymetrix Inc N D Ges D Staat Hybridisierung und sequenzierung von nukleinsäuren
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5665066A (en) 1993-09-03 1997-09-09 Ultradent Products, Inc. Methods and apparatus for mixing and dispensing multi-part compositions
US5641867A (en) 1993-09-29 1997-06-24 The Trustees Of Columbia University In The City Of New York Antibody which specifically binds to endothelial-monocyte activating polypeptide II
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
AU687535B2 (en) 1994-03-16 1998-02-26 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6379897B1 (en) 2000-11-09 2002-04-30 Nanogen, Inc. Methods for gene expression monitoring on electronic microarrays
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6013483A (en) 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US5843655A (en) 1995-09-18 1998-12-01 Affymetrix, Inc. Methods for testing oligonucleotide arrays
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
EP1288299A3 (en) 1996-01-19 2003-12-17 Smithkline Beecham Plc TRNA synthetase
GB9601067D0 (en) 1996-01-19 1996-03-20 Smithkline Beecham Plc Novel compounds
EP0785262A1 (en) 1996-01-19 1997-07-23 Smithkline Beecham Plc Phenylalanyl-tRNA synthetase from Staphylococcus aureus
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5837196A (en) 1996-01-26 1998-11-17 The Regents Of The University Of California High density array fabrication and readout method for a fiber optic biosensor
EP0937159A4 (en) 1996-02-08 2004-10-20 Affymetrix Inc SPECIATION OF MICROORGANISMS FROM MICROPLATES AND CHARACTERIZATION OF THE PHENOTYPES THEREOF
US6114122A (en) 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US6238866B1 (en) 1996-04-16 2001-05-29 The United States Of America As Represented By The Secretary Of The Army Detector for nucleic acid typing and methods of using the same
US5795758A (en) 1997-04-18 1998-08-18 Smithkline Beecham Corporation DNA encoding histidyl tRNA synthetase variant from Streptococcus pneumoniae
GB9607993D0 (en) 1996-04-18 1996-06-19 Smithkline Beecham Plc Novel compounds
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US5853993A (en) 1996-10-21 1998-12-29 Hewlett-Packard Company Signal enhancement method and kit
ATE259056T1 (de) 1996-11-06 2004-02-15 Sequenom Inc Verfahren zur massenspektrometrie
US5804386A (en) 1997-01-15 1998-09-08 Incyte Pharmaceuticals, Inc. Sets of labeled energy transfer fluorescent primers and their use in multi component analysis
US6309824B1 (en) 1997-01-16 2001-10-30 Hyseq, Inc. Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
DE69833758T2 (de) 1997-06-13 2006-08-31 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips
US6333179B1 (en) 1997-06-20 2001-12-25 Affymetrix, Inc. Methods and compositions for multiplex amplification of nucleic acids
US5858720A (en) 1997-07-23 1999-01-12 Smithkline Beecham Corporation Hiss
US5882892A (en) 1997-07-23 1999-03-16 Smithkline Beecham Corporation Asps
US6511803B1 (en) 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6054274A (en) 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
US6013449A (en) 1997-11-26 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Probe-based analysis of heterozygous mutations using two-color labelling
AU740830B2 (en) 1998-01-29 2001-11-15 Glaucus Proteomics B.V. High density arrays for proteome analysis and methods and compositions therefor
WO1999039001A2 (en) 1998-02-02 1999-08-05 Amersham Pharmacia Biotech Ab Nucleic acid analysis method
US6083726A (en) 1998-02-03 2000-07-04 Lucent Technologies, Inc. Methods for polynucleotide synthesis and articles for polynucleotide hybridization
JP2002502977A (ja) 1998-02-04 2002-01-29 インビトロジェン コーポレイション マイクロアレイとその使用
JP2002505110A (ja) * 1998-03-04 2002-02-19 オニックス ファーマシューティカルズ，インコーポレイティド 遺伝物質の高生産性発現のためのバキュロウイルス発現系及び方法
US6428960B1 (en) * 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6284497B1 (en) 1998-04-09 2001-09-04 Trustees Of Boston University Nucleic acid arrays and methods of synthesis
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
US6268210B1 (en) 1998-05-27 2001-07-31 Hyseq, Inc. Sandwich arrays of biological compounds
US6800286B1 (en) 1998-08-19 2004-10-05 The Regents Of The University Of Colorado Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
US6306643B1 (en) 1998-08-24 2001-10-23 Affymetrix, Inc. Methods of using an array of pooled probes in genetic analysis
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6316193B1 (en) 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
ATE316152T1 (de) 1998-10-27 2006-02-15 Affymetrix Inc Komplexitätsmanagement und analyse genomischer dna
US6263287B1 (en) 1998-11-12 2001-07-17 Scios Inc. Systems for the analysis of gene expression data
AU776679B2 (en) 1998-11-13 2004-09-16 Children's Hospital Of Los Angeles Methods of facilitating vascular growth
US6309828B1 (en) 1998-11-18 2001-10-30 Agilent Technologies, Inc. Method and apparatus for fabricating replicate arrays of nucleic acid molecules
US6245518B1 (en) 1998-12-11 2001-06-12 Hyseq, Inc. Polynucleotide arrays and methods of making and using the same
US6351712B1 (en) 1998-12-28 2002-02-26 Rosetta Inpharmatics, Inc. Statistical combining of cell expression profiles
AU2965500A (en) 1999-01-15 2000-08-01 Gene Logic, Inc. Immobilized nucleic acid hybridization reagent and method
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6177248B1 (en) 1999-02-24 2001-01-23 Affymetrix, Inc. Downstream genes of tumor suppressor WT1
EP1159615A2 (en) 1999-03-10 2001-12-05 National Institutes of Health, as represented by the Secretary, Department of Health and Human Services of the Government Universal protein array system
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU4058100A (en) 1999-04-09 2000-11-14 Arcturus Engineering, Inc. Generic cdna or protein array for customized assays
US6284465B1 (en) 1999-04-15 2001-09-04 Agilent Technologies, Inc. Apparatus, systems and method for locating nucleic acids bound to surfaces
US6268141B1 (en) 1999-05-12 2001-07-31 Beckman Coulter, Inc. Immobilization of unmodified biopolymers to acyl fluoride activated substrates
JP2003527087A (ja) 1999-08-13 2003-09-16 イェール・ユニバーシティ バイナリーコード化配列タグ
US6171797B1 (en) 1999-10-20 2001-01-09 Agilent Technologies Inc. Methods of making polymeric arrays
US6548060B1 (en) 1999-11-18 2003-04-15 Sunghoon Kim Anti-apoptotic use of human glutaminyl-tRNA synthetase with two consecutive pro-apoptotic mediators
US6372431B1 (en) 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
DE19957827C2 (de) 1999-11-25 2003-06-12 Epigenomics Ag Verwendung eines Oligomer-Arrays mit PNA- und/oder DNA-Oligomeren auf einer Oberfläche
US6383749B2 (en) 1999-12-02 2002-05-07 Clontech Laboratories, Inc. Methods of labeling nucleic acids for use in array based hybridization assays
US20070042392A1 (en) 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20030165921A1 (en) 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
US20030158400A1 (en) 2000-02-03 2003-08-21 Tang Y. Tom Novel nucleic acids and polypeptides
RU2316599C2 (ru) 2000-02-03 2008-02-10 Рисерч Дивелопмент Фаундейшн Передающие сигнал аптамеры, которые преобразуют сигнал распознавания молекулы в дифференциальный сигнал
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020128187A1 (en) 2000-02-03 2002-09-12 Tang Y. Tom Novel nucleic acids and polypeptides
US6267152B1 (en) 2000-02-18 2001-07-31 Wisconsin Label Corporation Hang tag and method of applying hang tag to an elongated object
US6376191B1 (en) 2000-03-22 2002-04-23 Mergen, Ltd. Microarray-based analysis of polynucleotide sequence variations
JP4868681B2 (ja) * 2000-03-31 2012-02-01 ザ スクリプス リサーチ インスティチュート 血管新生の調節のために有用なヒトアミノアシル−ｔＲＮＡシンテターゼポリペプチド
US7144984B2 (en) * 2000-03-31 2006-12-05 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7273844B2 (en) * 2000-03-31 2007-09-25 The Scripps Research Institute Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1322818A (zh) 2000-05-09 2001-11-21 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶10和编码这种多肽的多核苷酸
WO2001088162A2 (en) 2000-05-16 2001-11-22 Genway Biotech, Inc. Methods and vectors for generating antibodies in avian species and uses therefor
AU2001256780A1 (en) 2000-05-18 2001-11-26 Nihon University, School Juridical Person Method for examining ischemic conditions
JP2004510407A (ja) 2000-05-25 2004-04-08 インサイト・ゲノミックス・インコーポレイテッド アミノアシルｔＲＮＡ合成酵素
EP1297338B1 (en) 2000-06-05 2007-04-18 Novartis Vaccines and Diagnostics, Inc. Microarrays for performing proteomic analyses
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
US6386749B1 (en) 2000-06-26 2002-05-14 Affymetrix, Inc. Systems and methods for heating and mixing fluids
US6380377B1 (en) 2000-07-14 2002-04-30 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
JP2002071687A (ja) 2000-08-31 2002-03-12 Canon Inc 変異遺伝子のスクリーニング方法
WO2002031463A2 (en) 2000-08-31 2002-04-18 Motorola, Inc. High density column and row addressable electrode arrays
CN1341727A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——甲硫氨酰tRNA合成酶35.09和编码这种多肽的多核苷酸
CN1341725A (zh) 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人苏氨酰－tRNA合成酶48.73和编码这种多肽的多核苷酸
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2001292959A1 (en) 2000-09-22 2002-04-02 Clontech Laboratories, Inc. Highly sensitive proteomic analysis methods and kits and systems for practicing the same
CN1352242A (zh) 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人谷氨酰tRNA合成酶12.65和编码这种多肽的多核苷酸
CN1352252A (zh) 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人II类氨酰基－tRNA合成酶11.77和编码这种多肽的多核苷酸
EP1349939A2 (en) 2000-12-15 2003-10-08 Incyte Genomics, Inc. Aminoacyl trna synthetases
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2004524021A (ja) 2001-01-12 2004-08-12 エクセリクシス・インコーポレイテッド ＨｉｓＲＳをターゲッティングすることによるＳＲＥＢＰ経路の調節
IL157558A0 (en) 2001-02-23 2004-03-28 Scripps Research Inst TRYPTOPHANYL-tRNA SYNTHETASE DERIVED POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
US6903189B2 (en) * 2001-03-21 2005-06-07 The Scripps Research Institute Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
US20030215827A1 (en) 2001-05-22 2003-11-20 Henry Yue Aminoacyl trna synthetases
KR100405919B1 (ko) 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
US20040018505A1 (en) 2001-06-29 2004-01-29 Lee Ernestine A. Aminoacyl trna synthetases
US6632611B2 (en) 2001-07-20 2003-10-14 Affymetrix, Inc. Method of target enrichment and amplification
US6872529B2 (en) 2001-07-25 2005-03-29 Affymetrix, Inc. Complexity management of genomic DNA
WO2003009813A2 (en) 2001-07-26 2003-02-06 Novartis Ag Methods of treating neuropilin-mediated diseases
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2003103044A (ja) 2001-09-28 2003-04-08 Fuji Photo Film Co Ltd ゲーム装置
US20040048290A1 (en) 2001-12-13 2004-03-11 Lee Ernestine A Aminoacyl trna synthetases
US7011945B2 (en) 2001-12-21 2006-03-14 Eastman Kodak Company Random array of micro-spheres for the analysis of nucleic acids
US20040101879A1 (en) * 2002-01-11 2004-05-27 Cynthia Seidel-Dugan Srebp pathway modulation through targeting hisrs
US20060193830A1 (en) 2002-03-20 2006-08-31 Hauswirth William W Raav vector compositions and methods for the treatment of choroidal neovascularization
WO2003094848A2 (en) 2002-05-10 2003-11-20 Incyte Corporation Nucleic acid-associated proteins
WO2003094862A2 (en) 2002-05-13 2003-11-20 Rigel Pharmaceuticals, Inc. tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
KR100515016B1 (ko) 2002-07-22 2005-09-15 재단법인서울대학교산학협력재단 ｐ43을 유효성분으로 하는 창상 치료용 약학적 조성물
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US7011949B2 (en) 2002-09-30 2006-03-14 Agilent Technologies, Inc. Methods and compositions for producing labeled probe nucleic acids for use in array based comparative genomic hybridization applications
WO2004060262A2 (en) 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2006517533A (ja) 2003-01-23 2006-07-27 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路のアクチベーターを用いる自己免疫疾患の治療
US7028629B2 (en) 2003-02-03 2006-04-18 Richard Walcome Self-sealing port light assembly
KR100575251B1 (ko) * 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
WO2005073250A2 (en) 2004-01-28 2005-08-11 Lorantis Limited Medical treatment using an rna1 targeting a human notch signalling pathway member
JP2009521905A (ja) 2004-03-05 2009-06-11 アプレラ コーポレイション 冠動脈心疾患に関連する遺伝的多型、その検出方法および使用
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
KR100599454B1 (ko) * 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 ａｉｍ3의 신규 용도
ES2439390T3 (es) 2004-06-04 2014-01-22 The Scripps Research Institute Composiciones y procedimiento para el tratamiento de enfermedades neovasculares
US8282921B2 (en) * 2004-08-02 2012-10-09 Paul Glidden tRNA synthetase fragments
US20060079673A1 (en) 2004-08-02 2006-04-13 Paul Glidden Polynucleotides encoding tRNA synthetase fragments and uses thereof
US20060078553A1 (en) 2004-10-07 2006-04-13 Paul Glidden Diverse multi-unit complexes including a tRNA synthetase fragment
US20060024288A1 (en) * 2004-08-02 2006-02-02 Pfizer Inc. tRNA synthetase fragments
NZ554895A (en) 2004-11-03 2009-06-26 Almac Diagnostics Ltd Transcriptome microarray technology and methods of using the same
EP1657232A1 (en) 2004-11-05 2006-05-17 Cellzome Ag Use of S-enantiomers of alpha-sustituted aryl acetic acids for the prevention of Alzheimer's disease
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
CN101111222A (zh) 2005-02-01 2008-01-23 伊玛吉恩有限公司 刺激胶原蛋白合成和/或kgf表达的方法
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
KR100689274B1 (ko) 2005-03-30 2007-03-08 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질
US7842467B1 (en) 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
WO2007064941A2 (en) 2005-12-02 2007-06-07 The Scripps Research Institute Angiogenic tyrosyl trna synthetase compositions and methods
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2640064A1 (en) 2006-01-23 2007-07-26 Imagene Co., Ltd. Novel peptide and use thereof
NZ573407A (en) 2006-05-26 2012-09-28 Obodies Ltd Ob fold domains
WO2008007818A1 (en) 2006-07-13 2008-01-17 Seoul National University Industry Foundation Novel use of aimp1 for controlling glucose level
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
MX2009008270A (es) 2007-02-01 2009-08-12 Imagene Co Ltd Polipeptido novedoso que tiene actividad anti-tumoral.
US20100138941A1 (en) * 2007-04-27 2010-06-03 Imagene Co., Ltd. Method for screening immune modulator
WO2009114623A2 (en) 2008-03-11 2009-09-17 University Of North Carolina At Chapel Hill Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same
EP2307046B1 (en) 2008-06-11 2017-01-25 aTyr Pharma, Inc. Thrombopoietic activity of tyrosyl-trna synthetase polypeptides
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
CN102124104A (zh) * 2008-08-18 2011-07-13 财团法人首尔大学校产学协力财团 通过调节赖氨酰tRNA合成酶的细胞水平控制癌症转移或癌细胞移动的方法
WO2010041913A2 (ko) 2008-10-10 2010-04-15 서울대학교산학협력단 Grs 단백질 또는 이의 단편의 신규한 용도
KR101067817B1 (ko) 2008-10-10 2011-09-27 서울대학교산학협력단 Ａｉｍｐ1 폴리펩티드에 대한 항체를 포함하는 관절염 진단용 조성물
KR101067815B1 (ko) * 2009-02-05 2011-09-27 서울대학교산학협력단 제1형 당뇨병의 신규한 진단 마커
WO2010096170A2 (en) 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
ES2552773T3 (es) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
CA2755784C (en) 2009-03-16 2020-03-24 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
EP2414513B1 (en) 2009-03-31 2015-10-28 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
ES2535951T3 (es) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidil ARNt sintetasas para reducir la inflamación
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
US8828685B2 (en) 2010-02-04 2014-09-09 The Scripps Research Institute Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater

Also Published As

Publication number Publication date
US20140371294A1 (en) 2014-12-18
JP5730280B2 (ja) 2015-06-03
US20130243766A1 (en) 2013-09-19
CN107574157A (zh) 2018-01-12
US20170114148A1 (en) 2017-04-27
EP3255146A1 (en) 2017-12-13
US11078299B2 (en) 2021-08-03
AU2010226726A1 (en) 2011-10-20
US10017582B2 (en) 2018-07-10
JP6166241B2 (ja) 2017-07-19
US20190031775A1 (en) 2019-01-31
JP2018046857A (ja) 2018-03-29
ES2742251T3 (es) 2020-02-13
EP2408905A2 (en) 2012-01-25
CN104830812A (zh) 2015-08-12
EP2408905A4 (en) 2012-12-19
US8404242B2 (en) 2013-03-26
US10526419B2 (en) 2020-01-07
EP3255146B1 (en) 2019-05-15
ES2638779T3 (es) 2017-10-24
JP2012520681A (ja) 2012-09-10
US10941214B2 (en) 2021-03-09
WO2010107825A3 (en) 2011-03-03
US9605265B2 (en) 2017-03-28
US20200231704A1 (en) 2020-07-23
CN102428175A (zh) 2012-04-25
WO2010107825A2 (en) 2010-09-23
US8753638B2 (en) 2014-06-17
CA2755784A1 (en) 2010-09-23
HK1247243B (zh) 2020-02-28
AU2010226726A8 (en) 2014-08-14
DK2408905T3 (da) 2017-08-28
US20100297149A1 (en) 2010-11-25
US20220098327A1 (en) 2022-03-31
CA2755784C (en) 2020-03-24
EP2408905B1 (en) 2017-05-10
JP2017055768A (ja) 2017-03-23
JP2015034176A (ja) 2015-02-19
AU2010226726B8 (en) 2014-08-14
CN104830812B (zh) 2017-09-05
AU2010226726B2 (en) 2014-07-03
US20200216564A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
DK3255146T3 (da) Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2388266T3 (da) Fusionsmolekyler og IL-15-varianter
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2391920A4 (en) ATTACHABLE OPTICAL ELEMENT DEVICES AND ASSOCIATED METHODS
DK2376791T3 (da) Afstandsindretning og fastgørelsesindretning med afstandsindretning
DK2337809T4 (da) Polycarbonat-polyolsammensætninger og fremgangsmåder
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
BR112012011910A2 (pt) dispositivo e método
DK2120591T3 (da) Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf
DK2865361T3 (da) Tåreimplantater og tilhørende fremgangsmåder
BRPI0914558A2 (pt) dispositivo e métodos de manuseio tunular
BRPI0807225A2 (pt) Dispositivo e método endocirúrgico
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
DK2349430T3 (da) KATETERISERINGANORDNING og -kit
DK2283041T3 (da) Humaniserede anti-faktor d-antistoffer og anvendelser deraf
BRPI1007767A2 (pt) dispositivo de colocação, e, aparelho de afixação reversível
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
BRPI0816907A2 (pt) Método e dispositivo
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider